The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Did they pay to much for Andor? They did increase their offer about three times before they bought them. The sp rose dramatically so it falls dramatically? High PE and low dividend? I don't know. Not really that worried.
Hard to see why this company has fallen 30pc in a few weeks. Can't see any obvious reason. Suggestions?
debt they have taken on weighing down the price. It looks quite a lot. Anyway, I bought in today
"Andor launches new ultrasensitive OEM camera for superior Spectroscopy in the NIR 01 May 2014 Research-grade performance in a robust and compact OEM package. Andor, an Oxford Instruments company and world leader in scientific imaging and spectroscopy solutions, today announced the launch of its most sensitive, OEM-dedicated NIR spectroscopy detector to date. The iVac 316 offers the latest innovation in sensor technology with an unsurpassed combination of high sensitivity in the NIR region, high resolution 15 µm pixels and broadest spectral range (+10% greater than traditional spectroscopy sensors). The ‘Low Dark Current – Deep Depletion’, or LDC-DD, technology builds on the benefits of traditional Back Illuminated - Deep Depletion (BI-DD) sensors but offers an order of magnitude lower dark current."
New Cryofree® platform for quantum computing applications 07 May 2014 "Oxford Instruments Omicron NanoScience have developed a new Cryofree platform for quantum computing applications offering lower temperatures, more sample space and higher cooling power than any other system on the market. TritonXL extends the capabilities of the market leading TritonTM dilution refrigerator and beats all temperature records for cryofree dilution refrigerators by cooling samples as large as 430 mm in diameter to ≤ 4 milliKelvin in less than 36 hours."
Well run innovative company going cheap. Got myself £29 k worth.
BUY from the 21 March
Unless im reading this share all wrong, now is a fantastic level to buy at, obviously Ukraine saga is only thing that will prevent this from flying upwards.....im willing to take the chance!
mean to dip in and out of this excellent company, but it was a no brainer not to buy back in 1st November as mentioned below. I've sold again, but will certainly buy back in shortly, as there will be steady growth from a company that has first class management and workforce.
to start buying OXIG whilst they are this low price
Im not entirely sure why whenever they release a good set of numbers the share price always dips?
Oxford Instruments: Jefferies initiates with a target price of 1740p and a hold recommendation.
Oxford Instruments, a company which providers high technology tools and systems for industry and research, has told investors that it has seen a continuation of the trend seen in the first half of the year, with growth in the Nanotechnology Tools sector and continued softness in the Industrial Products sector since the start of October. The group added that its Service sector has continued to grow as it integrates its existing business with the Platinum Medical Imaging business that it acquired last year. "Save as described in this statement, there has been no significant change in the financial position of the group in the period," the company told investors. "Our broad spread of geographies and technologies, and our strong pipeline of new products help us to remain resilient in the current uncertain economic environment. "The board anticipates that Oxford Instruments will continue to make good progress, in line with its expectations for the remainder of the financial year and consistent with its 14 cubed objectives."
Oxford Instruments: Numis increases target price from 1380p to 1825p and maintains an add rating.
Jan 10 (Reuters) - Oxford Instruments PLC: * UBS starts with buy rating; target price 170 0p
The acquisition of Asylum Research is in line with Oxford Instruments' 14 Cubed objectives, to achieve a 14% average compound annual growth rate in revenues and a 14% return on sales by the year ending March 2014. This acquisition contributes to the planned acquisition element of the revenue growth objective. While Asylum Research is expected to deliver less than the 14% targeted margin in this and the next financial year, following the acquisition the 14 Cubed margin target for the Group remains unchanged. Commenting on the acquisition, Jonathan Flint, Chief Executive Officer of Oxford Instruments, stated: "The acquisition of Asylum Research significantly increases our footprint in the nanotechnology space and complements our strong position in electron microscopes with a presence in another fundamental nanotechnology measurement technique. "The acquisition also gives us access to the rapidly growing bio-nano market as it allows customers to perform analysis of organic samples in their natural liquid environments, something which cannot readily be done using electron microscopes."
High technology tools and systems provider Oxford Instruments has announced the acquisition of microscope provider Asylum Research Corporation. The acquisition is subject to customary conditions and is expected to be completed before the end of December 2012. Asylum is being acquired from its management for an initial debt free, cash-free consideration of $32.0 million with a deferred element of up to $48.0 million payable over three years dependent on its performance over that period. Asylum Research generated Earnings Before Interest and Taxation (EBIT) of $1.1 million in the twelve months to December 31 2011 from revenue in the same period of $19.6 million. It had gross assets of $6.2 million as at December 31 2011. The acquisition will be funded from existing facilities. Based in Santa Barbara, California, Asylum Research is an established US company with subsidiaries in the UK, Germany and Taiwan. Its scanning probe microscopes technology is used by academic and industrial customers for a wide range of materials and bioscience applications.
Commenting on the acquisition, Jonathan Flint, Chief Executive of Oxford Instruments, stated: "The acquisition of Asylum Research significantly increases our footprint in the nanotechnology space and complements our strong position in electron microscopes with a presence in another fundamental nanotechnology measurement technique. The acquisition also gives us access to the rapidly growing bio-nano market as it allows customers to perform analysis of organic samples in their natural liquid environments, something which cannot readily be done using electron microscopes."
The acquisition of Asylum Research is in line with Oxford Instruments' 14 Cubed objectives, to achieve a 14% average compound annual growth rate in revenues and a 14% return on sales by the year ending March 2014. This acquisition contributes to the planned acquisition element of the revenue growth objective. While Asylum Research is expected to deliver less than the 14% targeted margin in this and the next financial year, following the acquisition the 14 Cubed margin target for the Group remains unchanged. As part of Oxford Instruments there will be significant scope to accelerate the inherent strong growth of Asylum Research's end markets and to deliver substantial improvements in margin over time based on increasing scale. Approximately 60% of Asylum Research turnover comes from customers working in the materials science area where the customer base and routes to market are shared with Oxford Instruments. This opens opportunities for market synergies and the development of new integrated products. The remainder of Asylum Research's turnover is in the bio-nano area where SPM instruments are used for research into soft materials, such as DNA. This market provides a new growth opportunity for Oxford Instruments.
Oxford Instruments plc: Acquisition of Asylum Research Corp. Oxford Instruments plc ("Oxford Instruments" or "the Group"), a leading provider of high technology tools and systems for industry and research, announces the acquisition of Asylum Research Corporation ("Asylum Research"), a leading provider of Scanning Probe Microscopes (SPM). The acquisition is subject to customary conditions and is expected to be completed before the end of December 2012. Asylum Research is an established US company based in Santa Barbara, California, with subsidiaries in the UK, Germany and Taiwan. Its SPM technology is used to image and characterise the properties of surfaces and structures down to the atomic scale providing invaluable information to enable development and exploitation at the nanoscale. Its products are used by academic and industrial customers across the world for a wide range of materials and bioscience applications. The combination of Oxford Instruments and Asylum Research strengthens the Group's Nanotechnology Tools sector. SPM is a fundamental nanotechnology measurement technique and complements the existing portfolio of products and technologies within the Group. Asylum Research is being acquired from its management for an initial debt free, cash free consideration of US$32.0 million with a deferred element of up to US$48.0 million payable over three years dependent on its performance over that period. Asylum Research generated Earnings Before Interest and Taxation (EBIT) of $1.1 million in the twelve months to 31 December 2011 from revenue in the same period of $19.6 million. It had gross assets of $6.2 million as at 31 December 2011. The acquisition will be funded from existing facilities.
Oxford Instruments: Liberum Capital raises target price from 1445p to 1515p, buy rating kept.
Oxford Instruments, the high-tech tools and systems provider, said order intake from its research markets remains good but there has been some softness in its industrial markets. In a statement prepared for the firm's annual general meeting, Chairman Nigel Keen said the company's Nanotechnology Tools business has made a good start to the new fiscal year, which kicked off in April. "The launch of our new XMax large area detector in August has further consolidated our position as a leading provider of advanced material analysis equipment," Keen claimed. The Industrial division is also trading in line with expectations, while the Service division has "performed well", with the recently acquired Platinum Medical Imaging business bedding in nicely. "The board anticipates that Oxford Instruments will continue to make progress in line with our expectations for the financial year," Keen declared.
bilbo - the Market seems to have focussed rather unfairly on "Order intake from our research markets remains good although as expected there has been some softness in our industrial markets." - well that appears to be the only slight negative in the RNS
http://www.investegate.co.uk/Article.aspx?id=201209110700049360L